Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase
inhibitors, mandate regular updating of concepts and management. A European LeukemiaNet …

The therapeutic landscape of chronic myeloid leukemia (CML) has profoundly changed over
the past 7 years. Most patients with chronic phase (CP) now have a normal life expectancy. …

Normal haematopoietic cells use complex systems to control proliferation, differentiation
and cell death. The control of proliferation is, in part, accomplished through the ligand-induced …

Characterizing the transcriptome of individual cells is fundamental to understanding complex
biological systems. We describe a droplet-based system that enables 3′ mRNA counting …

Background The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL
tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to …

The classification of myeloid neoplasms and acute leukemias was last updated in 2016
within a collaboration between the World Health Organization (WHO), the Society for …

Background In a randomized trial, 1106 patients with chronic myeloid leukemia (CML) in
chronic phase were assigned to imatinib or interferon alfa plus cytarabine as initial therapy. We …

Imatinib mesylate is considered standard of care for first-line treatment of chronic phase
chronic myeloid leukemia (CML-CP). In the phase III, randomized, open-label International …

Background Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for
patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses on …

Abstract 1126 Poster Board I-148 Background The IRIS study demonstrated superior safety
and efficacy of imatinib (IM) relative to interferon-αa + cytarabine. Based on results from this …